Näytä suppeat kuvailutiedot

PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

Karra H; Nykanen M; Gurvits N; Repo H; Kronqvist P; Kurki S; Loyttyniemi E; Lintunen M; Talvinen K; Kuopio T; Soderstrom M

dc.contributor.authorKarra H
dc.contributor.authorNykanen M
dc.contributor.authorGurvits N
dc.contributor.authorRepo H
dc.contributor.authorKronqvist P
dc.contributor.authorKurki S
dc.contributor.authorLoyttyniemi E
dc.contributor.authorLintunen M
dc.contributor.authorTalvinen K
dc.contributor.authorKuopio T
dc.contributor.authorSoderstrom M
dc.date.accessioned2022-10-28T13:21:23Z
dc.date.available2022-10-28T13:21:23Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/164588
dc.description.abstractBackground: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed.Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival.Results: In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p = 0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052).Conclusions: PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material.
dc.language.isoen
dc.publisherBIOMED CENTRAL LTD
dc.titlePTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival
dc.identifier.urnURN:NBN:fi-fe2021042717417
dc.relation.volume17
dc.contributor.organizationfi=Auria Biopankki|en=Auria Biobank|
dc.contributor.organizationfi=kliinisen laitoksen yhteiset|en=Department of Clinical Medicine|
dc.contributor.organizationfi=biostatistiikka|en=Biostatistics|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, vsshp|
dc.contributor.organizationfi=biolääketieteen laitos, yhteiset|en=Institute of Biomedicine|
dc.contributor.organization-code2607100
dc.contributor.organization-code2607300
dc.contributor.organization-code2607005
dc.contributor.organization-code2607302
dc.converis.publication-id27375005
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/27375005
dc.identifier.jour-issn1471-2407
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.affiliatedauthorSöderström, Mirvamaaria
dc.okm.affiliatedauthorKronqvist, Pauliina
dc.okm.affiliatedauthorGurvits, Natalia
dc.okm.affiliatedauthorTalvinen, Kati
dc.okm.affiliatedauthorRepo, Heli
dc.okm.affiliatedauthorLöyttyniemi, Eliisa
dc.okm.affiliatedauthorKurki, Samu
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumberARTN 705
dc.relation.doi10.1186/s12885-017-3694-6
dc.relation.ispartofjournalBMC Cancer
dc.year.issued2017


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot